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Abstract
Background and Aims: Randomized, controlled trials of cardiac resynchronization therapy (CRT)
excluded patients with adult congenital heart disease (ACHD). We sought to explore long-term
clinical outcomes.
Methods and Results: In this single-center, observational study, events were collected from hos-
pital records on patients with structural ACHD (sACHD) and adults with ischemic (ICM) or non-
ischemic (NICM) cardiomyopathy undergoing CRT. Patients with sACHD (n = 23, age: 41.6 ±
13.5 years [mean ± standard deviation]) and adults with ICM (n = 533) or NICM (n = 458) were
followed-up for 4.1 years (median; interquartile range: 2.2-6.1). Total mortality was 5/23 (21.7%;
4.4 per 100 person-years) in sACHD, 221/533 (41.5%; 11.8 per 100 person-years) in ICM, and
154/458 (33.6%; 9.7 per 100 person-years) in NICM. In univariate analyses, total mortality in
sACHD was lower than in ICM (hazard ratio [HR]: 0.38; 95% confidence interval [CI] 0.15-0.91),
but similar to NICM (HR: 0.48, 95%CI 0.20-1.16). Cardiac mortality in sACHDwas similar to ICM
(HR: 0.78, 95% CI 0.32-1.92) and NICM (HR: 1.12, 95% CI 0.45-2.78). Heart failure (HF) hospi-
talization rates were similar to ICM (HR: 0.44, 95% CI 0.11-1.77) and NICM (HR: 0.75, 95% CI
0.18-3.08). In multivariate analyses, no differences emerged in total mortality, cardiac mortality,
or HF hospitalization between sACHD andNICMor ICM, after adjustment for age, sex, New York
HeartAssociation class, diabetes, atrial rhythm,QRSduration,QRSmorphology, systemic ventric-
ular ejection fraction, andmedical therapy.
Conclusion: Total mortality, cardiac mortality, and HF hospitalization after CRT in patients with
sACHDwas similar to adults with ICMor NICM.
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1 INTRODUCTION
Cardiac resynchronization therapy (CRT) is an established treatment
for adult patients with heart failure (HF), impaired left ventricular (LV)
function, and a wide QRS complex.1 Supporting evidence has emerged
from numerous randomized, controlled trials and meta-analyses
thereof.2 Consequently, CRT is now widely accepted as a Class I
indication (level of evidence A) for selected patients with nonischemic
(NICM) or ischemic (ICM) cardiomyopathy.
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It has been shown that CRT in adult congenital heart disease
(ACHD) is feasible3,4; the Pediatric and Congenital Electrophysiol-
ogy Society/Heart Rhythm Society (PACES/HRS) expert consensus
statement on the recognition and management of arrhythmias in
ACHD5 states that CRT is indicated in patients with ACHD with sinus
rhythm, a systemic ventricular ejection fraction (SVEF) <35%, left
bundle branch block (LBBB), a QRS complex>150ms (spontaneous or
paced), and aNewYorkHeart Association (NYHA) class II to IV (ambu-
latory) symptoms. These indications, which are classified as a level
Pacing Clin Electrophysiol. 2019;1–8. wileyonlinelibrary.com/journal/pace 1
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F IGURE 1 Age distribution according to etiology of
cardiomyopathy. ACHD= adult congenital heart disease;
ICM= ischemic cardiomyopathy; NICM= nonischemic
cardiomyopathy [Color figure can be viewed at
wileyonlinelibrary.com]
of evidence “B,” are based on presumed surrogate markers of clinical
outcomes from adult populations with congenitally normal hearts,
none of which have been validated against “hard endpoints” in ACHD.
Moreover, no studies of CRT in the pediatric or ACHDpopulation have
involved randomization, and clinical outcome data are also lacking,
even from observational studies.5 In addition, not all observational
studies of CRT in ACHD have distinguished between structural ACHD
(sACHD) and nonstructural ACHD, such as dilated cardiomyopathy
and congenital complete heart block.5 In the absence of firm evidence
in its favor, CRT in ACHD is not permitted in some countries, notably
Japan.6
In the context of the challenges in undertaking randomized, con-
trolled studies in a young, heterogenous population with rare condi-
tions, we sought to compare outcomes of CRT in adults with sACHD,
NICM, or ICM.
2 METHODS
This is a retrospective study of patients with sACHD who had their
first CRT device implantation at a tertiary referral center for ACHD
(Queen Elizabeth Hospital, Birmingham, United Kingdom) fromMarch
2002 to January 2017. Outcomes were compared with a population
of adult patients with NICM or ICM who also underwent CRT device
implantation in the same time period. Some adult patients with NICM
or ICM have been included in previous publications.7 The study was
approved by the Clinical Audit Department at the Queen Elizabeth
Hospital, which permits publication of clinical data for the purposes
of service evaluation. The study conforms with the Declaration of
Helsinki.
TheUnited KingdomNational Institute of Clinical Excellence (NICE)
guidelines in 2007 recommended CRT-pacing (CRT-P) rather than
CRT-defibrillation (CRT-D) for patients with NICM and indications for
CRT.With a subsequent guideline change in 2014 recommendingCRT-
D in NICM,8 the proportion of CRT-D recipients increased thereafter.
No specific guidelines have been issued by NICE or indeed any other
guideline group as to the choice of CRT-P or CRT-D in the ACHD
population. Consequently, device choice was dependent on physician's
discretion.
2.1 Endpoints
The primary endpoint was total mortality and the secondary end-
point was cardiac mortality, which included cardiac transplantation or
implantation of a ventricular assist device. We also included the ancil-
lary endpoint of unplanned HF hospitalization. Mortality data were
collected through medical records and cross-checked with a national
mortality database. Clinical outcome data were collected every
6 months by investigators who were blinded to clinical and imaging
data.
2.2 Device therapy
Device implantationwas undertaken using standard transvenous tech-
niques under general or local anesthesia and intravenous sedation,
or via a thoracotomy with epicardial lead deployment under general
anesthesia. The transvenous implantation technique in patients with
sACHD varied according to the anatomy of the systemic ventricle and
the location and accessibility of the coronary sinus and its tributaries.
Implanters aimed at implanting the LV lead in a posterolateral vein.
There was no systematic use of QLV interval, as evidence for this
approach predated most of the implantations. The choice of CRT-D
and CRT-P was based on the occurrence of sustained ventricular
arrhythmias prior to implantation. After implantation, patients were
followed-up in dedicated device clinics. Up to 2013, patients in sinus
rhythm underwent trans-mitral Doppler-directed optimization of
atrioventricular delay using an iterative technique prior to discharge
and at every scheduled visit. Routine echocardiographic optimization
was abandoned thereafter and was only undertaken in symptomatic
nonresponders. Backup atrial pacing was set at 60 beats/min, and
the pacing mode was set to DDDR with an interventricular delay of
0-20 ms (left ventricular [LV] first), according to clinician's discretion.
In patients with permanent atrial fibrillation, systemic ventricular and
nonsystemic ventricular leads were implanted and a CRT generator
was used, plugging the atrial port and programming to a ventricular
triggered mode, according to physician's choice. Atrioventricular
junction ablation was undertaken according to physicians’ decision.
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TABLE 1 Characteristics of the study group
sACHD ICM NICM P-value
N 23 533 458
Sex (male), n (%) 13 (56.52) 425 (79.74) 294 (64.19) <.001
Age (years) 41.6± 13.5 74.4± 9.2 71.4± 11.9 <.001
NYHA class, n (%)
I 3 (13.64) 20 (3.88) 26 (5.96) .304
II 3 (13.64) 68 (13.18) 68 (15.6)
III 15 (68.18) 395 (76.55) 317 (72.71)
IV 1 (4.55) 33 (6.4) 25 (5.73)
Device type, n (%)
CRT-D 6 (26.09) 346 (64.92) 114 (24.89) <.001
CRT-P 17 (73.91) 187 (35.08) 344 (75.11)
Upgrades from pacemaker 13 (56.5) 75 (14.07) 98 (21.40) <.001
Comorbidity, n (%)
Diabetes mellitus 2 (8.70) 162 (30.39) 88 (19.21) <.001
Hypertension 1 (4.35) 160 (30.02) 136 (29.69) .029
CABG – 148 (27.77) 32 (6.99) <.001
ECG variables
Sinus rhythm, n (%) 18 (78.26) 349 (65.48) 286 (62.45) .228
Atrial fibrillation, n (%) 5 (21.74) 184 (34.52) 172 (37.55)
LBBB, n (%) 15 (65.22) 426 (79.92) 412 (89.96) <.001
QRS duration (ms) 170.5± 30.8 152.8± 21.8 158.2± 21.8 <.001
Medication, n (%)
Loop diuretics 22 (95.65) 513 (96.25) 431 (94.1) .284
ACEIs/ARAs 21 (91.30) 459 (86.12) 391 (85.37) .711
𝛽-Blockers 21 (91.30) 395 (74.11) 302 (65.94) .002
MRAs 11 (47.83) 247 (46.34) 181 (39.52) .088
SVEF (%) 32.8± 12.6 24.2± 9.3 25.1± 9.5 <.001
Note. Variables are expressed asmean± standard deviation, unless indicated otherwise.
Abbreviations: ACEIs= angiotensin-converting enzyme inhibitors; ARAs= angiotensin receptor antagonists; CABG= coronary artery bypass grafting; CRT-
D = cardiac resynchronization therapy-defibrillation; CRT-P = cardiac resynchronization therapy-pacing; ECG = electrocardiogram; ICM = ischemic car-
diomyopathy; LBBB = left bundle branch block; MRAs =mineralocorticoid receptor antagonists; NICM = nonischemic cardiomyopathy; NYHA =New York
Heart Association; sACHD= structural adult congenital heart disease; SVEF= systemic ventricular ejection function.
aDifferences between the groups from analysis of variance for continuous variables and from chi-squared tests for categorical variables.
bPermanent, persistent, and paroxysmal atrial fibrillation (AF).
Patients underwent a clinical assessment on the day prior to implanta-
tion and at 1, 3, and every 6months following device implantation.
2.2.1 Statistical analysis
Continuous variables are expressedasmean (±standarddeviation) and
compared using the Student's t-test. Categorical variables were com-
pared using the chi-squared statistic. Kaplan-Meier curves and the log-
rank testwere used to assess survival. Cox proportional hazardmodels
were used to compare risks of the various endpoints. Proportionality
hypotheses were verified by visual examination of log (survival)
graphs to ensure parallel slopes, and by plotting Schoenfeld residuals.
Statistical analyses were undertaken using Stata 14 (StataCorp,
College Station, TX, USA). A two-sided P ≤ .05 was considered
statistically significant.
3 RESULTS
3.1 Baseline characteristics
The age distribution in the three study groups is shown in Figure 1. As
shown in Table 1, patients with sACHDwere mostly female (P < .001).
As expected, they were younger (P < .001) and were less likely to have
diabetes, hypertension, or a previous coronary artery bypass grafting.
No differences emerged with respect to atrial rhythm, but left bundle
branch block (LBBB) was less prevalent in the sACHD group (P< .001).
The sACHD group had a higher proportion of patients on 𝛽-blockers
(P= .002) but the groups were well matched for uptake of loop diuret-
ics, angiotensin converting enzyme inhibitors (ACEIs) or angiotensin
receptor antagonists (ARAs), and mineralocorticoid receptor antag-
onists. In the sACHD group, the SVEF was higher (P < .001) and a
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TABLE 3 Univariate analyses
Events
ACHD (n= 23) ICM (n= 533) NICM (n= 458)
Total mortality 5 (21.7) 221 (41.5) 154 (33.6)
Cardiac mortality 5 (21.7) 106 (19.9) 67 (14.6)
HF hospitalization 2 (8.69) 84 (15.8) 45 (9.82)
Note. Results are expressed in terms of absolute number and percent-
age of events. ACHD = adult congenital heart disease; HF = heart failure;
ICM= ischemic cardiomyopathy; NICM= nonischemic cardiomyopathy.
greater proportionof patients underwentupgrades frompacemaker to
CRT (P< .001). The characteristics of individual patients and operation
details are shown in Table 2.
3.2 Outcomes
Over 4.1 years (median 4.1 years; interquartile range: 2.2-6.1 years),
total mortality was 5/23 (21.7%; 4.4 per 100 person-years) in the
sACHD group, 221/533 (41.5%; 11.8 per 100 person-years) in
the ICM group, and 154/458 (33.6%; 9.7 per 100 person-years) in
the NICM group (Table 3). There were two patients who underwent
implantations of a LV assist device, one in the ICMgroup and one in the
NICM group. None underwent cardiac transplantation. Kaplan-Meier
survival analyses are shown in Figure 2. In univariate Cox proportional
hazards models, total mortality in sACHD was lower than in ICM
(hazard ratio [HR]: 0.38; 95% confidence interval [CI] 0.15-0.91), but
similar to NICM (HR: 0.48, 95% CI 0.20-1.16). Cardiac mortality in
sACHD was similar to ICM (HR: 0.78, 95% CI 0.32-1.92) and NICM
(HR: 1.12, 95% CI 0.45-2.78). Similarly, HF hospitalization was similar
to ICM (HR: 0.44, 95%CI 0.11-1.77) andNICM (HR: 0.75, 95%CI 0.18-
3.08). Age, sex, NYHA class, diabetes, atrial rhythm, QRS duration,
LVEF, and treatment with loop diuretics, ACEIs/ARAs, and 𝛽-blockers
also emerged as significant predictors of total mortality (Online
Appendix) and these variables were included in multivariate analyses.
Multivariate analyses showed no differences in total mortality, cardiac
mortality, or HF hospitalization between sACHD and ICM or NICM
(Table 4).
4 DISCUSSION
This is the first study to address long-termoutcomes ofCRT in patients
with ACHD.5 We found that after CRT, total mortality, cardiac mortal-
ity, andHFhospitalization in sACHDwere similar to adultswith ICMor
NICM, after adjustment for potential confounders.
Although CRT is being undertaken in the pediatric and adult
population with sACHD, studies in its favor have only focused on
surrogate predictors of outcome. In a study of 20 patients, Sakaguchi
et al showed that in a mixed population of children and adult patients
with a systemic LV or single ventricular physiology, CRT led to a
reduction in ventricular volume.9 In a retrospective study comprising
children with CHD (n = 73) or cardiomyopathy (n = 16) (median age
12.8 years; follow-up of 4months), the SVEF improved after CRT.4 In a
F IGURE 2 Clinical outcomes after cardiac resynchronization
therapy according to etiology of cardiomyopathy. ACHD= adult
congenital heart disease; ICM= ischemic cardiomyopathy;
NICM= nonischemic cardiomyopathy [Color figure can be viewed at
wileyonlinelibrary.com]
retrospective study of 60 children and adults with CHD aged between
5 months and 47 years, which included 46 patients with ACHD and
14 patients with dilated cardiomyopathy (mean age 15 years), CRT
was associated with an increase in SVEF from 36% to 42% (P < .001)
and an improvement in functional status was observed in 87% of
patients with follow-up data.10 Merchant et al also found that in adult
patients with repaired tetralogy of Fallot, improvements in LVEF were
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TABLE 4 Univariate andmultivariate analyses
sACHD vs ICM sACHD vsNICM
Univariate analyses
Total mortality 0.38 0.15 0.91 0.031 0.48 0.20 1.16 0.103
Cardiacmortality 0.78 0.32 1.92 0.592 1.12 0.45 2.78 0.809
HF hospitalization 0.44 0.11 1.77 0.247 0.75 0.18 3.08 0.685
Multivariate analyses
Total mortality 1.27 0.42 3.79 0.674 2.66 0.75 9.41 0.128
Cardiacmortality 3.19 0.98 10.4 0.054 2.65 0.66 10.6 0.168
HF hospitalization 1.51 0.29 7.88 0.625 1.95 0.38 10.0 0.422
Notes. Comparison of events in patients with sACHD, using ICM andNICMas reference. Results are expressed in terms of hazard ratios and 95% confidence
intervals. In multivariate analyses, there was covarite adjustment for age, sex, New York Heart Association class, diabetes, atrial rhythm, QRS duration, left
ventricular ejection fraction, and treatment with loop diuretics, angiotensin-converting enzyme inhibitors/angiotensin receptor antagonists, and 𝛽-blockers
as covariates (seeOnline Appendix).
Abbreviation:HF=heart failure; ICM= ischemic cardiomyopathy;NICM=nonischemic cardiomyopathy; sACHD= structural adult congenital heart disease.
sustained after 53.4 months.11 In a recent retrospective study includ-
ing 48 patients with ACHD (median age: 47 years) followed-up over
a median of 2.6 years, 77% responded to CRT either by improvement
of NYHA functional class and/or systemic ventricular function.3 These
data, which are based on surrogate outcome measures, are consistent
with our findings that outcomes of CRT in sACHD are similar to adult
patients with NICMor ICM.
In this study, more than half of patients with sACHDwere upgraded
from pacemakers to CRT. This is not unexpected, as both sACHD
and operations for sACHD lead to conduction system disturbances.
Although we do not have access to the SVEF prior to pacemaker
implantation, the SVEF at the time of upgrade was severely impaired.
This could be due to the natural progression of CHD, but we can-
not discount the possibility that subpulmonary ventricular pacing may
have contributed to a deterioration in systemic ventricular function.
In this respect, right ventricular (RV) pacing is associated with impair-
ment of LV function and a risk of HF in adult patients with NICM or
ICM.12–15 In patients with sick sinus syndrome, up to 40% develop HF
with RV pacing.16,17 In the Dual Chamber and VVI Implantable Defib-
rillator (DAVID) study12,18 and theMode Selection Trial (MOST),13 RV
pacing was also associated with a higher risk of HF hospitalization.
In patients with CHD, Moak et al showed an improvement in clinical
status after upgrading from pacemakers to CRT in six patients aged
11.3 yearswithNICM.19 No data are available in patientswith sACHD.
Unfortunately, our sample is also too small to explore the effects of
upgrading to CRT in sACHD. It would appear, however, that the long-
term outcome of CRT in patients with sACHD is comparable to adult
patients with NICM, despite the fact that more than half of patients
were upgraded from pacemakers. Whether or not pacing the systemic
ventricle in patients with sACHD and conventional indications for pac-
ing is preferable to pacing the nonsystemic ventricle remains unex-
plored.
In this study, patient selection for CRT was driven by the pres-
ence of HF symptoms, a wide QRS complex (intrinsic or paced) and
impaired SV function, in the background of maximum tolerated med-
ical therapy. Importantly, there will be a selection bias, which was not
addressed, insofar as some sACHD patients would not have under-
gone CRT because of problems with access to peripheral or coronary
sinus veins. Physician preference therefore played a role in patient
selection.
4.1 Limitations
The small sample size is the main limitation of this study. Given the
trends observed herein, larger numbers could show that CRT is bet-
ter in ACHD after CRT compared to non-ACHD. Clearly, a congen-
itally abnormal heart is not the same as a structural normal heart
with acquired disease. By definition, age is an inescapable covariate
of ACHD. Although we have included age in statistical analyses, the
biological interaction between age and ACHD cannot be corrected for
by statistical means. Caution is therefore appropriate when interpret-
ing the results of these analyses. Unfortunately, follow-up echocardio-
grams were not systematically collected and therefore, we are unable
to comment on the effects of CRT on LV reverse remodeling. Last, we
do not have control groups that were not treated with CRT and there-
fore,we cannot comment on the relative benefit ofCRT, but only on the
possible effects of the underlying “substrate.”
5 CONCLUSIONS
We found that after CRT, total mortality, cardiac mortality, or HF hos-
pitalization in sACHD was similar to patients with ICM or NICM. Our
findings have emerged in the context that observational studies in
the sACHD have not addressed long-term outcomes in patients with
sACHD and that a randomized controlled trial of CRT in this patient
population is unlikely to emerge.
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